NCT02334527 - Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2015

Primary Completion Date

December 2, 2016

Study Completion Date

September 28, 2017

Conditions

Metastatic Urothelial Carcinoma (UC)

Interventions

DRUG

Palbociclib

125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.

Trial Locations (3)

North Carolina Cancer Hospital (UNC), Chapel Hill

Vanderbilt-Ingram Cancer Center, Nashville

University of Michigan, Ann Arbor